Press Releases

Apr 13, 2022
Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic Malignancies ALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted Fast Track Designation (FTD) by the U.S. FDA in March 2022 SOUTH SAN FRANCISCO, Calif.
Displaying 11 - 20 of 23
Print Page
Email Alerts
RSS Feeds
Investor Contacts